超导管大动脉替换优化策略:顶重叠,指导方位对齐,尺寸和定位
Saima Siddique1, Resha Khanal1, Amit N Vora1,2
1University of Pittsburgh Medical Center Heart and Vascular Institute Harrisburg, PA.
US cardiology
|November 27, 2024
概括
超导管大动脉置换 (TAVR) 正在扩展到年轻患者身上. 本综述涵盖了并发症,风险因素以及诸如 cusp 叠加和 commissural alignment 等新技术,以改善 TAVR 的结果.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 医疗器械 医疗器械
背景情况:
- 通过导管的大动脉置换 (TAVR) 越来越多地用于年轻的低风险患者.
- 识别患有术后并发症风险的患者对于TAVR的成功至关重要.
- 并发症包括副膜泄漏,假肢与患者不匹配以及导电异常.
研究的目的:
- 审查TAVR相关并发症的发病率和风险因素.
- 突出新的方法来减少这些并发症.
- 讨论策略,以保持冠状动脉接入TAVR后,特别是在年轻的患者.
主要方法:
- 对TAVR并发症和风险因素的当前文献的综述.
- 专注于新一代跨导管心脏门.
- 讨论尖端重叠技术,以获得精确的植入深度.
- 分析冠状动脉通道的 commissural 调整策略.
主要成果:
- 尖端重叠技术优化了光镜成像,用于精确的TAVR植入.
- 这种技术最大限度地减少了与心脏导电系统的相互作用.
- 在TAVR后使冠状动脉通道成为可能时,commissural对齐具有重要意义.
- 经过修改的交付技术显示出改善 commissural 调整的前景.
结论:
- 新的TAVR技术和技巧可以减轻程序复杂性.
- 精确的植入深度和 commissural 调整是成功TAVR结果的关键.
- 保持冠状动脉通道是TAVR年轻患者的一个重要考虑因素.
更多相关视频
06:59Improved Registration of 3D CT Angiography with X-ray Fluoroscopy for Image Fusion During Transcatheter Aortic Valve Implantation
Published on: June 3, 2018
10.5K
09:57Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
Published on: January 20, 2022
2.5K
相关概念视频
01:17Aortic Regurgitation IV: Nursing Management
12
A nurse managing a patient with aortic regurgitation begins with a comprehensive assessment, including a review of the patient's medical history, family history, and lifestyle factors. During the cardiac examination, the nurse listens for heart sounds and checks for signs of valve abnormalities. The nurse also observes for symptoms such as dyspnea, orthopnea, and paroxysmal nocturnal dyspnea and assesses the patient's endurance and daily activity tolerance.Based on the findings, the nurse...
12
01:25Mitral Regurgitation III: Medical Management
4
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
4